The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
December 27th 2024
Individuals who refused a pneumococcal vaccine were associated with low collective responsibility and confidence in vaccine efficacy and safety.
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Diseases
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Diseases
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Diseases, Pulmonology
View More
Insights in Influenza Immunization: The Long-Term Care Pharmacist’s Role in Improving Health Outcomes in At-Ri...
1.0 Credit / Immunization, Infectious Diseases
View More
Pneumococcal Vaccine Candidate Shows Promise in Adults Aged 65 Years and Older
April 20th 2023VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.
Read More
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive Candidiasis
March 24th 2023Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.
Read More
Study Shows PCV13 Followed by PPSV23 Protects Against Pneumococcal Diseases in Patients With SCD
March 6th 2023The immunological efficacy of the 13-valent conjugate pneumococcal vaccine followed by 23-valent polysaccharide vaccine has been poorly documented in adult patients with sickle cell disease.
Read More